Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Purpose: We conducted a phase I/II study to evaluate durvalumab (D; anti-PD-L1) in combination with tremelimumab (T; anti-cytotoxic T-lymphocyte antigen 4) in pediatric patients with relapsed/refractory solid tumors. Patients and methods: The dose-finding phase (phase I) assessed the safety and pharmacokinetics of D+T at two dose levels to determine the recommended phase II dose (RP2D). The primary endpoint for the dose-expansion phase (phase II) was antitumor activity (by Response Evaluation Criteria in Solid Tumors v1.1) at the RP2D. Assessment of circulating cells reflecting immune cell activation was a secondary endpoint. Results: Based on safety and pharmacokinetic data in the dose-finding phase (n = 29), the adult-equivalent RP2D was determined as D (30 mg/kg) + T (1 mg/kg). In the dose-expansion phase, 21 patients (sarcoma, n = 11; solid tumors, n = 10) were treated at the RP2D. Of patients with sarcoma, none achieved an objective response and one had stable disease ≥7 weeks. Of the patients with solid tumors, one (chordoma) had a confirmed partial response (10.8 months duration) and one (renal cell carcinoma) had stable disease ≥7 weeks. Treatment-related adverse events occurred in 76% of patients (19% as grade 3 or 4). No adverse events leading to death were reported. Across both phases treatment with D+T resulted in an increase in CD4+Ki67+ T cells. Conclusions: D (30 mg/kg) + T (1 mg/kg) had limited antitumor activity in this pediatric population; however, the safety profile was manageable and consistent with the known safety profile in adult patients, with no new safety concerns identified. Clinical trial registration: ClinicalTrials.gov, identifier NCT03837899; EudraCT, identifier 2018-003118-42.
Source: Frontiers in Oncology
Institutions: Great Ormond Street Hospital, University College London, Institute of Cancer Research, Royal Marsden Hospital, Centre National de la Recherche Scientifique, Inserm, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Centre de Recherche en Cancérologie de Marseille, Hôpital de la Timone, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, Cohen Children's Medical Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, AstraZeneca (United States), AstraZeneca (United Kingdom)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: durvalumab, tremelimumab, PD-L1 inhibitors, CTLA-4 blockade, immune checkpoint inhibitors, combination immunotherapy, pediatric solid tumors, relapsed/refractory cancer, sarcoma, chordoma, renal cell carcinoma, dose-finding, recommended phase 2 dose, anticancer activity, treatment safety, immune cell activation
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7161272841
